Feedback / Questions
IAM1363 - Iambic Therap
https://www.businesswire.com/news/home/20250604655326/en/Iambic-Completes-Dose-Escalation-in-Ongoing-Phase-11B-Study-of-Lead-Program-IAM1363-a-Small-Molecule-Inhibitor-of-Wild-Type-and-Oncogenic-HER2-Mutant-Proteins
Jun 4, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next